title: Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder.
abstract: OBJECTIVE
  To estimate continuation rates, complications, and psychiatric hospitalizations among women with bipolar disorder using levonorgestrel-releasing or copper-containing intrauterine devices (IUDs) as compared with those using depot medroxyprogesterone acetate or sterilization for birth control.
  
  
  METHODS
  Data for this cohort study were obtained from a nationwide health insurance claims database on an employed, commercially insured population. Women aged 18-44 years with a prior diagnosis of bipolar disorder (n=849) who were using the levonorgestrel intrauterine system, a copper-containing IUD, depot medroxyprogesterone acetate, or sterilization were evaluated. Outcomes included continuation rates over a 12-month interval, infectious and noninfectious complications, and hospitalizations for bipolar disorder or depression.
  
  
  RESULTS
  Women using an IUD were more likely than those using depot medroxyprogesterone acetate to continue the method for at least 12 months (copper-containing IUD, 86%; levonorgestrel intrauterine system, 87%). In comparison, only 31% of those who initiated depot medroxyprogesterone acetate received three more injections during the next year (P<.001). No significant differences were noted in infectious or noninfectious complications by contraceptive type. Finally, no differences were observed in the number of hospitalizations for bipolar disorder or depression among the four contraceptive groups.
  
  
  CONCLUSIONS
  More women with bipolar disorder continued using IUDs at one year than women using depot medroxyprogesterone acetate. The rates of complications and psychiatric hospitalizations were not different among women using an IUD, depot medroxyprogesterone acetate, or sterilization.
  
  
  METHODS
  II.
authors: From the Departments of Obstetrics and Gynecology and Preventive Medicine and Community Health and the Center for Interdisciplinary Research in Women's Health, University of Texas Medical Branch, Galveston, Texas; and the Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois.
authors: Abbey B
authors: AB
authors: Berenson
authors: Humera
authors: H
authors: Asem
authors: Alai
authors: A
authors: Tan
authors: Gregg S
authors: GS
authors: Wilkinson
mesh_terms: D000328:Adult; D001714:Bipolar Disorder; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007435:Intrauterine Devices, Copper / Q000009:adverse effects*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D010349:Patient Compliance / Q000706:statistics & numerical data*; D013245:Sterilization, Reproductive / Q000009:adverse effects; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate